Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus–Induced Murine Bacteremia
Authors:
Open Access
- 28 November 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 209 (9) , 1469-1478
Abstract
Lysins are bacteriophage-derived enzymes that degrade bacterial peptidoglycans. Lysin CF-301 is being developed to treat Staphylococcus aureus because of its potent, specific, and rapid bacteriolytic effects. It also demonstrates activity on drug-resistant strains, has a low resistance profile, eradicates biofilms, and acts synergistically with antibiotics. CF-301 was bacteriolytic against 250 S. aureus strains tested including 120 methicillin-resistant S. aureus (MRSA) isolates. In time-kill studies with 62 strains, CF-301 reduced S. aureus by 3-log10 within 30 minutes compared to 6–12 hours required by antibiotics. In bacteremia, CF-301 increased survival by reducing blood MRSA 100-fold within 1 hour. Combinations of CF-301 with vancomycin or daptomycin synergized in vitro and increased survival significantly in staphylococcal-induced bacteremia compared to treatment with antibiotics alone (P < .0001). Superiority of CF-301 combinations with antibiotics was confirmed in 26 independent bacteremia studies. Combinations including CF-301 and antibiotics represent an attractive alternative to antibiotic monotherapies currently used to treat S. aureus bacteremia.Keywords
This publication has 41 references indexed in Scilit:
- Novel Strategy to Prevent Otitis Media Caused by Colonizing Streptococcus pneumoniaePLOS Pathogens, 2007
- The Recombinant Phage Lysin LysK Has a Broad Spectrum of Lytic Activity against Clinically Relevant Staphylococci, Including Methicillin-Resistant Staphylococcus aureusJournal of Bacteriology, 2005
- Issues in Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents: Kill Curves versus MICAntimicrobial Agents and Chemotherapy, 2004
- Phage Lytic Enzyme Cpl-1 as a Novel Antimicrobial for Pneumococcal BacteremiaInfection and Immunity, 2003
- The CHAP domain: a large family of amidases including GSP amidase and peptidoglycan hydrolasesTrends in Biochemical Sciences, 2003
- A bacteriolytic agent that detects and kills Bacillus anthracisNature, 2002
- Rapid Killing of Streptococcus pneumoniae with a Bacteriophage Cell Wall HydrolaseScience, 2001
- Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzymeProceedings of the National Academy of Sciences, 2001
- Bacterial Biofilms: A Common Cause of Persistent InfectionsScience, 1999
- SH3 domains in prokaryotesTrends in Biochemical Sciences, 1999